Atomoxetine – further delay in change of funded brand and open access
17 March 2020
Due to manufacturing delays, we have delayed the listing of Generic Partners brand atomoxetine by 2 months.
This means that the Special Authority criteria will not be removed until 1 June 2020.
New dates for listing of Generic Partners atomoxetine
|Generic Partners atomoxetine listed in Schedule (Sections B and H)||1 June 2020|
|Special Authority criteria removed (Sections B and H)||1 June 2020|
|Hospital sole supply||1 August 2020|
|Subsidy reduction for currently funded Strattera brand (reference pricing)||1 August 2020|
|Community sole supply||1 November 2020|
|Delisting of Strattera from Section B||1 November 2020|
|Brand switch fee applies for Generic Partners||1 November 2020 to 1 January 2021|
10 January 2020 delay notification
What we're doing
PHARMAC is advising all interested parties that there is a further delay in the listing of a new funded brand of atomoxetine and removal of the current funding restrictions. The following reflects the most up-to-date information.
The listing of the Generic Partners’ brand of atomoxetine capsules (10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg) has been further delayed and will now be listed from 1 April 2020. Generic Partners noted that Eli Lilly will continue supplying the current funded brand Strattera in the interim.
Removal of Special Authority and sole supply will also be delayed.
This change was the subject of a consultation letter dated 10 December 2018. The subsequent decision was notified on 31 January 2019. It was originally communicated that the Generic Partners’ brand of atomoxetine would be funded from 1 July 2019 and all funding restrictions would be removed from atomoxetine at the same time.
Generic Partners has recently advised PHARMAC of a delay in supplying its brand of atomoxetine. As a result, Generic Partners' atomoxetine will be listed on 1 April 2020.
|Generic Partners atomoxetine listed in Schedule (Sections B and H)||1 April 2020|
|Special Authority criteria removed (Sections B and H)||1 April 2020|
|Hospital sole supply||1 June 2020|
|Subsidy reduction for currently funded Strattera brand (reference pricing)||1 June 2020|
|Community sole supply||1 September 2020|
|Delisting of Strattera from Section B||1 September 2020|
|Brand switch fee applies for Generic Partners||1 September 2020 to 1 December 2020|
As a result, the listing date in Section B and Part II of Section H of the Pharmaceutical Schedule for all strengths will be moved to 1 April 2020, and the Special Authority and the Hospital Indication Restriction for atomoxetine will now be removed from 1 April 2020.
This also means the subsidy reduction in Section B for the currently funded Strattera brand will now occur from 1 June 2020. The Strattera brand will be delisted from Part II of Section H of the Pharmaceutical Schedule (hospital listing) on 1 June 2020 and from Section B (community listing) from 1 September 2020.
Generic Partners will be the sole subsidised brand from 1 September 2020 in the community until 30 June 2022 and will be the Hospital Supply Status brand of atomoxetine until 30 June 2022, with a 1% DV Limit.
A Brand Switch Fee will apply to Generic Partners’ brand for the period of 1 September 2020 until 1 December 2020.
If you have any questions about this decision, you can email us at email@example.com; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Last updated: 17 March 2020